Shots:
- The EC has approved Imfinzi monotx. for the treatment of LS-SCLC adults whose disease has not progressed after receiving Pt-based CRT; regulatory review underway in Japan & other regions
- Approval was based on P-III (ADRIATIC) trial (n=730) assessing Imfinzi (1500mg, IV, Q4W) with or without Imjudo (75mg, IV, Q4W × 4 cycles) followed by Imfinzi (for ~24mos.) vs PBO
- Study showed reduced risk of death by 27% (mOS: 55.9 vs 33.4mos.), where 57% vs 48% pts were alive at 3yrs., while also depicting improved PFS by 24% (mPFS: 16.6 vs 9.2mos.), where 46% vs 34% pts had no disease progression at 2yrs. Data was published in The NEJM
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
